Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Racotumomab in High-risk Neuroblastoma
NCT02998983Phase 2Completed
- Sponsor
- Laboratorio Elea Phoenix S.A.
- Start
- Nov 2016
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of racotumomab in neuroblastoma (2 arms), sponsored by Laboratorio Elea Phoenix S.A. Primary endpoint: Number of participants who elicit an immune response at 1 year. Started Nov 2016; status: completed.
02
Drugs
racotumomab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02998983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998983.